북미 익막약 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 익막약 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Sep 2022
  • North America
  • 350 Pages
  • 테이블 수: 50
  • 그림 수: 51

>북미 익막약 시장, 질병 유형(진행성 익막 및 위축성 익막), 단계(2단계, 3단계, 1단계), 치료(인공 눈물/국소 윤활제 및 스테로이드 안약), 제형(안약, 안연고, 기타), 구매 방식(처방 및 일반 의약품(OTC)), 인구 유형(노인 및 성인), 최종 사용자(병원, 전문 병원, 가정 의료, 기타), 유통 채널(소매 약국, 병원 약국, 온라인 약국, 기타), 국가(미국, 캐나다, 멕시코) - 산업 동향 및 2029년까지의 예측.

북미 익막약 시장

북미 익막약 시장 분석 및 통찰력

익막은 눈꺼풀 틈새 안의 변연 결막에서 시작하여 각막으로 진행되는 흔한 안구 표면 병변입니다. 이는 "날개"를 의미하는 그리스어 pterygos에서 따온 이름입니다. 이 병변은 측두엽보다 비강 변연에서 더 자주 발생하며 특징적인 날개 모양이 있습니다. 자외선 노출은 익막의 발생과 밀접한 관련이 있습니다. 자외선 노출 병력이 있거나 적도에 더 가깝게 사는 사람은 발병률이 더 높습니다(야외 작업). 특정 연구에 따르면 남성이 여성보다 발병률이 다소 높은데, 이는 자외선 노출률이 더 높기 때문일 수 있습니다.

북미 익막약 시장

북미 익막약 시장

발적, 염증, 눈 모양 변화를 일으킬 수 있습니다. 난시를 일으킬 수 있으며, 이는 시력을 흐리게 만들 수 있습니다. 눈 앞부분을 덮는 희끄무레하거나 분홍빛 성장이 생길 수 있습니다. 한쪽 또는 양쪽 눈에 영향을 미칠 수 있습니다.

익막염은 전체 눈 검사를 통해 눈의 앞쪽 부분을 현미경으로 검사하여 진단하며, 눈의 흰자위에서 각막에 조직이 자라는 모습을 통해 진단합니다.

Data Bridge Market Research에 따르면 북미 익막약 시장이 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 5.8%로 성장할 것으로 분석되었습니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2015로 사용자 정의 가능)

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

질병 유형(진행성 익막 및 위축성 익막), 단계(2단계, 3단계, 1단계, 4단계), 치료(인공 눈물/국소 윤활제 및 스테로이드 안약), 제형(안약, 안연고, 기타), 구매 방식(처방 및 일반의약품(OTC)), 인구 유형(노인 및 성인), 최종 사용자(병원, 전문 병원, 가정 의료, 기타), 유통 채널(소매 약국, 병원 약국, 온라인 약국, 기타)

적용 국가

미국, 캐나다, 멕시코

시장 참여자 포함

Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), Théa Laboratories (France), Wellona Pharma (India), Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan)

 North America Pterygium Drug Market Dynamics

Drivers

  • Rise in incidences and prevalence of ophthalmic disorders

According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator.

The most common causes of pterygium include long-term exposure to ultraviolet (UV) light from the sun (the most common cause) and eye irritation caused by hot, dry weather, wind, and dust. The affirmative factors state that this is the major driver for the North America pterygium drugs market.

  • Rise in the geriatric population

With the growing geriatric population across the globe, the prevalence of ophthalmic diseases with severe ocular pain is also growing. According to data provided published in "Global Prevalence of Blindness and Distance and Near Vision Impairment in 2020: progress towards the Vision 2020 targets and what the future holds" by "The Association for Research in Vision and Ophthalmology" (ARVO) estimated 41.9 million people were blind.

With the growing population, the pressure on the healthcare system is increasing. The demand for care and services is rising to treat the problem of Ophthalmol disorder, including pterygium. Therefore, the increasing geriatric population is a great opportunity for the North America pterygium drug market.

북미 익막약 시장

Opportunities

  • Programs and initiatives to reduce the burden of eye diseases

The International agency to prevent blindness has launched several programs and initiatives with well-reputed NGOs and corporates to spread awareness and reduce the burden of eye diseases.

For instance,

  • International Agency endorses our Children's Vision and an initiative co-founded by the Brien Holden Vision Institute and the Vision For Life fund (created by Essilor) for the Prevention of Blindness (IAPB)

Restraints/Challenges

  • High cost of eye treatment and medication

The growing prevalence of various ophthalmic disorders has also increased the necessity for timely treatments. However, the treatments and proper medication for ophthalmology disorders are not very cheap. Recent studies show that the price of topical steroids price is increasing in the past few years. Even though some topical ophthalmic steroids like prednisolone are mildly cheap, other advanced medications and eye drops are still expensive.

The North America pterygium drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pterygium drug market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The prevalence of ophthalmic disorders keeps showing a surge in growth due to the rise in chemical industries and pollution worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface.

According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator. Pterygium prevalence has been reported to range from 0.3 to 29% worldwide.

The North America pterygium drug market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence are some data variables available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohot multivariate statistical model for forecasting the market in the growth period.

Post-COVID-19 Impact on North America Pterygium Drug Market

COVID-19 has negatively affected the market. Lockdowns and isolations during pandemics complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.

Recent Development

  • In January 2022, Alcon announced the launch of Systane complete preservative-free lubricant eye drops in Europe. The product works to provide all-in-one dry eye relief with one drop by hydrating the layers of the tear film. This has helped the company to increase its product portfolio

North America Pterygium Drug Market Scope

The North America pterygium drug market is categorized into eight notable segments based on disease type, stages, treatment, and formulation, mode of purchase, population type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

  • Progressive Pterygium
  • Atrophic Pterygium

Based on disease, the North America pterygium drug market is segmented into progressive pterygium and atrophic pterygium.

Stages

  • Stage 1
  • Stage 2
  • Stage 3

Based on stages, the North America pterygium drug market is segmented into stage 1, stage 2, stage 3,

Treatment

  • Artificial Tears/Topical Lubricants
  • Steroid Eye Drops

Based on treatment, the North America pterygium drug market is segmented into artificial tears/topical lubricants and steroid eye drops.

Formulation

  • Eye Drops
  • Eye Ointments
  • Others

Based on formulation, the North America pterygium drug market is segmented into eye drops, eye ointments, and others.

Mode of Purchase

Based on the mode of purchase, the North America pterygium drug market is segmented into prescription and over-the-counter (OTC).

Population Type

  • Geriatric
  • Adults

Based on population type, the North America pterygium drug market is segmented into geriatric and adults.

End-User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Based on end-user, the North America pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

북미 익막약 시장

Based on distribution channels, the North America pterygium drug market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

North America Pterygium Drug Market Regional Analysis/Insights

The North America pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, and formulation, mode of purchase, population type, end-user, and distribution channel as referenced above.

The countries covered in the North America pterygium drug market report are the U.S., Canada, and Mexico.

The North America pterygium drug market is expected to grow due to the presence of big market players in the region and an established healthcare system. The U.S. is expected to dominate the North America pterygium drug market in terms of market share and market revenue. It will continue to flourish its dominance during the forecast period. This is due to the high prevalence of disease in the region.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Pterygium Drug Market Share Analysis

북미 익막약 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 유럽의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 익막약 시장과 관련된 회사의 초점에만 관련이 있습니다.

북미 익막증 약물 시장의 주요 기업으로는 Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, OASIS Medical, Alcon, Santen Pharmaceutical Co., Ltd. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA PTERYGIUM DRUG MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 NORTH AMERICA PTERYGIUM DRUG MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 CLASS SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 NORTH-AMERICA PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES

5 PIPELINE ANALYSIS

6 NORTH-AMERICA PTERYGIUM DRUG MARKET: REGULATIONS

6.1 REGULATION IN THE NORTH-AMERICA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS

7.1.2 RISE IN GERIATRIC POPULATION

7.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES

7.2 RESTRAINTS

7.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION

7.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS

7.3 OPPORTUNITIES

7.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES

7.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME

7.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES

7.4 CHALLENGES

7.4.1 STRINGENT RULES & REGULATIONS

7.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS

8 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 PROGRESSIVE PTERYGIUM

8.3 ATROPHIC PTERYGIUM

9 NORTH AMERICA PTERYGIUM DRUG MARKET, BY STAGES

9.1 OVERVIEW

9.2 STAGE 2

9.3 STAGE 3

9.4 STAGE 1

10 NORTH AMERICA PTERYGIUM DRUG MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS

10.2.1 DEMULCENT

10.2.2 EMOLLIENTS

10.3 STEROID EYE DROPS

10.3.1 KETONE STEROIDS

10.3.1.1 PREDNOSOLONE

10.3.1.2 DEXAMETHASONE

10.3.1.3 FLUROMETHOLONE

10.3.1.4 OTHERS

10.3.2 ESTER STEROID (LOTERPREDNOL)

11 NORTH AMERICA PTERYGIUM DRUG MARKET, BY FORMULATION

11.1 OVERVIEW

11.2 EYE DROPS

11.2.1 EYE DROPS WITH PRESERVATIVES

11.2.2 PRESERVATIVE-FREE EYE DROPS

11.3 EYE OINTMENTS

11.4 OTHERS

12 NORTH AMERICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE

12.1 OVERVIEW

12.2 PRESCRIPTION

12.3 OVER THE COUNTER (OTC)

13 NORTH AMERICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE

13.1 OVERVIEW

13.2 GERIATRIC

13.3 ADULTS

14 NORTH AMERICA PTERYGIUM DRUG MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 HOME HEALTHCARE

14.5 OTHERS

15 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 RETAIL PHARMACIES

15.3 HOSPITAL PHARMACIES

15.4 ONLINE PHARMACIES

15.5 OTHERS

16 NORTH AMERICA PTERYGIUM DRUG MARKET, BY COUNTRY

16.1 U.S.

16.2 MEXICO

16.3 CANADA

17 NORTH AMERICA PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 ALCON

19.1.1 COMPANY SNAPSHOT

19.1.2 RECENT FINANCIALS

19.1.3 PRODUCT PORTFOLIO

19.1.4 RECENT DEVELOPMENTS

19.2 ABBVIE INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENT

19.3 BAUSCH & LOMB INCORPORATED

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 PRODUCT PORTFOLIO

19.3.4 RECENT DEVELOPMENT

19.4 JOHNSON & JOHNSON SERVICES, INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENTS

19.5 BAYER AG

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENTS

19.6 AKORN OPERATING COMPANY LLC

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 AMNEAL PHARMACEUTICALS LLC.

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 NOVARTIS AG

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 OASIS MEDICAL

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 PRESTIGE CONSUMER HEALTHCARE INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 SANTEN PHARMACEUTICAL CO., LTD.

19.11.1 COMPANY SNAPSHOT

19.11.2 RECENT FINANCIALS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 SIMILASAN CORPORATION

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENTS

19.13 THÉA LABORATORIES

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 WELLONA PHARMA

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 ZYDUS GROUP

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

TABLE 1 NORTH-AMERICA PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 15 U.S. PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 16 U.S. PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 17 U.S. PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 U.S. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 U.S. STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 U.S. KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 U.S. PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 22 U.S. EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 23 U.S. PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 24 U.S. PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 25 U.S. PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 26 U.S. PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 MEXICO PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 28 MEXICO PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 29 MEXICO PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 MEXICO ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 MEXICO STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 MEXICO KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 MEXICO PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 34 MEXICO EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 35 MEXICO PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 36 MEXICO PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 37 MEXICO PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 38 MEXICO PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 39 CANADA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 40 CANADA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 41 CANADA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 42 CANADA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 CANADA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 CANADA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 CANADA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 46 CANADA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 47 CANADA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 48 CANADA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 49 CANADA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 50 CANADA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 NORTH AMERICA PTERYGIUM DRUG MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA PTERYGIUM DRUG MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA PTERYGIUM DRUG MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA PTERYGIUM DRUG MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA PTERYGIUM DRUG MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA PTERYGIUM DRUG MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA PTERYGIUM DRUG MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA PTERYGIUM DRUG MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA PTERYGIUM DRUG MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA PTERYGIUM DRUG MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND RISE IN GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA PTERYGIUM DRUG MARKET FROM 2022 TO 2029

FIGURE 12 PROGRESSIVE PTERYGIUM IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA PTERYGIUM DRUG MARKET FROM 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH-AMERICA PTERYGIUM DRUG MARKET

FIGURE 14 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2021

FIGURE 15 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, 2021

FIGURE 19 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, LIFELINE CURVE

FIGURE 22 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2021

FIGURE 23 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 26 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2021

FIGURE 27 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, LIFELINE CURVE

FIGURE 30 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2021

FIGURE 31 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 34 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2021

FIGURE 35 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 38 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, 2021

FIGURE 39 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, CAGR (2022-2029)

FIGURE 41 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 43 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 44 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 45 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 NORTH AMERICA PTERYGIUM DRUG MARKET: SNAPSHOT (2021)

FIGURE 47 NORTH AMERICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021)

FIGURE 48 NORTH AMERICA PTERYGIUM DRUG MARKET: BY COUNTRY (2022 & 2029)

FIGURE 49 NORTH AMERICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021 & 2029)

FIGURE 50 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 51 NORTH AMERICA PTERYGIUM DRUG MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The North America Pterygium Drug Market will grow at a CAGR of 5.8% by 2029.
The high cost of eye treatment and medication are poised to restrict the North America Pterygium Drug Market growth.
The major players operating in the North America Pterygium Drug Market are Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), Théa Laboratories (France), Wellona Pharma (India), Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan).
The major countries covered in the North America Pterygium Drug Market are U.S., Canada, Mexico.